Approved, product-specific semaglutide versus an investigational triple agonist.
Bottom line: Semaglutide is sold in FDA-approved products. Retatrutide is still investigational, and FDA says it cannot be compounded under federal law. The 2026 Phase 3 figures come from a sponsor announcement; a full peer-reviewed paper is not yet available. [1–6]
| Semaglutide | Retatrutide | |
|---|---|---|
| Status | FDA-approved only as named products and labeled uses. [1,2] | Investigational and legally available only to clinical-trial participants; cannot be compounded under federal law. [4,6] |
| 2026 efficacy evidence | Product labels and peer-reviewed trials. | Sponsor reported 28.3% loss at 12 mg under the efficacy estimand and 25.0% under the treatment-regimen estimand at 80 weeks. [4] |
| Can trial doses be copied? | Use the exact approved label and prescription. | No. A trial protocol is not a consumer titration or preparation plan. [4,5] |
summary: Semaglutide is sold in FDA-approved products. Retatrutide is still investigational, and FDA says it cannot be compounded under federal law. The 2026 Phase 3 figures come from a sponsor announcement; a full peer-reviewed paper is not yet available. [1–6]
trials: []
No. It compares evidence and status. Use the exact approved label and prescriber plan, or a registered clinical-trial protocol if you are enrolled.
Educational evidence summary. Approved products, patient-specific compounded preparations, clinical-trial products, and research-market products are not interchangeable categories.
